ESPGHAN Guidelines on Pancreatic Lipase Supplementation in Infants
The provided evidence does not contain specific ESPGHAN guidelines for pancreatic enzyme replacement therapy (PERT) dosing in infants with pancreatic exocrine insufficiency. The available guidelines 1 address adult chronic pancreatitis rather than pediatric populations, and the ESPGHAN position paper 2 focuses on pancreatitis rather than providing specific enzyme dosing protocols for infants with exocrine insufficiency.
What the Evidence Actually Shows
General Principles from Available Guidelines
The ESPEN guidelines 1 establish that:
- Pancreatic enzymes taken with meals are the mainstay of treatment for exocrine pancreatic insufficiency
- Normal fat content (30% of total energy intake) should be maintained rather than restricting fat
- Enzymes should be taken with every meal and snack
- H2-antagonists or proton-pump inhibitors can be added if therapeutic resistance occurs despite adequate enzyme dosing
- Fat-soluble vitamins (A, D, E, K) should be supplemented if clinical deficiency is apparent
Emerging Evidence in Preterm Infants
Recent research provides insight into enzyme use in very preterm infants:
For very preterm infants (<32 weeks, <1500g) with documented low fecal elastase-1 (<200 µg/g), one observational study 3 used:
- 350 U lipase from Rhizopus oryzae with every meal via gavage
- Dosage doubled to 700 U once infants reached 1000g
- This resulted in significant improvement in weight gain (14.7 to 19.5 g/kg/day, p<0.001)
- Effects were most marked in infants receiving pasteurized milk rather than raw milk
Critical Diagnostic Considerations
Fecal elastase-1 (FE1) serves as the primary diagnostic biomarker but must be interpreted carefully in preterm infants 4:
- Serial testing is essential to distinguish true exocrine pancreatic insufficiency from physiologic pancreatic immaturity
- Persistent low values despite advancing gestational age suggest true insufficiency
- FE1 may normalize as infants mature, allowing discontinuation of therapy
Clinical Algorithm for Infant Management
Step 1: Confirm Diagnosis
- Obtain serial FE1 measurements (not single values)
- Document persistent malabsorption, steatorrhea, and growth failure
- Consider gestational age and feeding status in interpretation
Step 2: Nutritional Optimization Before or Concurrent with PERT
- Ensure adequate caloric intake
- Consider MCT-containing formulas (absorbed independent of lipase)
- Maintain normal fat intake (30% of calories) rather than restricting
- Provide frequent small meals
Step 3: Initiate PERT When Indicated
- Start when objective evidence of EPI exists (persistent low FE1 + clinical manifestations)
- Administer with every feeding
- Monitor weight gain, stool characteristics, and fat-soluble vitamin status
Step 4: Monitor and Adjust
- Reassess FE1 periodically as infants mature
- Consider discontinuation if FE1 normalizes and growth is adequate
- Add acid suppression if inadequate response despite appropriate dosing
Important Caveats
The absence of specific ESPGHAN infant dosing guidelines is a significant gap. The pediatric position paper 2 acknowledges that children with chronic pancreatitis need ongoing assessment for exocrine insufficiency but does not provide specific enzyme dosing protocols for infants.
Extreme caution is needed in extrapolating adult guidelines to infants due to:
- Different enzyme formulations and potencies
- Immature gastrointestinal physiology
- Risk of fibrosing colonopathy with excessive dosing (historical concern)
- Physiologic pancreatic immaturity in preterm infants that may resolve
The evidence for enzyme supplementation in preterm infants is emerging but limited 3, with only observational data available rather than randomized controlled trials.